Healthcare Industry News:   computer-aided detection 

Devices Radiology Oncology

 News Release - September 20, 2006

iCAD Releases Version 7.2 of its Computer-Aided Detection Technology for Mammography

Available Immediately, Version 7.2 Helps Radiologists Improve Screening and Workflow

NASHUA, N.H., Sept. 20 (HSMN NewsFeed) -- iCADŽ, Inc. (Nasdaq: ICAD ), an industry-leading provider of computer-aided detection (CAD) solutions for the early detection of cancer, today announced the release of a new version of its CAD software that will ship with all SecondLook 300 and SecondLook 700 systems.

iCAD's latest software, CAD v7.2, is a highly trained algorithm that automatically identifies and marks areas typically associated with cancer. The CAD software marks the primary indications of breast cancer in a consistent, logical manner that is closely aligned with standard mammography training. The result is an improved workflow for the radiologist and a higher rate of detection among users. In clinical studies, iCAD has been shown to find up to 72% of the cancers that had been missed on the previous mammogram exam.

"Though mammography has come a long way, there is still a need for increased sensitivity," said Rachel Brem, MD, Director of Breast Imaging and Intervention, The George Washington University Medical Center. "iCAD's latest software version has improved sensitivity to subtle cancers with fewer false positives and far more understandable indications. Tests at my facility showed a significant improvement in mass detection. Version 7.2 is a big step forward for iCAD."

CAD v7.2 offers users the following benefits:
  • Reduced false markings of vascular calcifications
  • Reduced false markings due to film noise or grain
  • Reduced false markings of lymph nodes
  • Reduced false markings due to linear structures
iCAD uses its patented advanced pattern recognition techniques to see subtle areas of concern. These are then analyzed using the highly trained intelligent computer-aided detection algorithm. iCAD has the ability to delve into each mammographic image in far greater range than the human eye can perceive. This results in iCAD's ability to identify subtle and often overlooked lesions.

"iCAD is committed to continuously innovating and advancing our technology to improve mammography," said Ken Ferry, Chief Executive Officer of iCAD, Inc. "These latest improvements provide radiologists with a more accurate tool, making early detection of breast cancer easier. We are already seeing increased demand from radiologists who realize the benefits of our technology."

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of computer-aided detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by almost one thousand women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's other filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this statement.

For iCAD Investor Relations, contact Kevin McGrath of Cameron Associates at 212-245-4577 or via email at

For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via email at

Source: iCAD

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.